HomeCompareFRTX vs PLD

FRTX vs PLD: Dividend Comparison 2026

FRTX yields 213.90% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRTX wins by $170.58M in total portfolio value
10 years
FRTX
FRTX
● Live price
213.90%
Share price
$0.94
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$177.09M
Annual income
$92,250,740.75
Full FRTX calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — FRTX vs PLD

📍 FRTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRTXPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRTX + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRTX pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRTX
Annual income on $10K today (after 15% tax)
$18,181.82/yr
After 10yr DRIP, annual income (after tax)
$78,413,129.64/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, FRTX beats the other by $73,945,158.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRTX + PLD for your $10,000?

FRTX: 50%PLD: 50%
100% PLD50/50100% FRTX
Portfolio after 10yr
$91.80M
Annual income
$48,753,588.46/yr
Blended yield
53.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

FRTX
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-18.7
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRTX buys
0
PLD buys
0
No recent congressional trades found for FRTX or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRTXPLD
Forward yield213.90%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$177.09M$6.50M
Annual income after 10y$92,250,740.75$5,256,436.18
Total dividends collected$167.49M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: FRTX vs PLD ($10,000, DRIP)

YearFRTX PortfolioFRTX Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$32,090$21,390.37$11,255$555.24+$20.8KFRTX
2$98,489$64,151.88$13,062$1,018.59+$85.4KFRTX
3$289,391$184,008.00$15,903$1,926.67+$273.5KFRTX
4$814,951$505,302.85$20,839$3,823.32+$794.1KFRTX
5$2,201,885$1,329,887.07$30,464$8,166.08+$2.17MFRTX
6$5,714,120$3,358,103.33$52,054$19,457.30+$5.66MFRTX
7$14,258,620$8,144,511.98$109,886$54,188.93+$14.15MFRTX
8$34,250,418$18,993,694.31$304,030$186,451.18+$33.95MFRTX
9$79,287,637$42,639,690.06$1,166,125$840,813.32+$78.12MFRTX
10$177,088,513$92,250,740.75$6,504,190$5,256,436.18+$170.58MFRTX

FRTX vs PLD: Complete Analysis 2026

FRTXStock

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Full FRTX Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this FRTX vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRTX vs SCHDFRTX vs JEPIFRTX vs OFRTX vs KOFRTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.